BPC-157

BPC-157 is a 15-amino-acid peptide, a fragment of a larger protein originally identified in human gastric juice. The name (Body Protection Compound) reflects its proposed role in tissue defense and repair.

The animal literature on BPC-157 is substantial. Rodent studies have documented accelerated tendon and ligament healing, gastrointestinal mucosal protection, and effects on angiogenic and growth-factor pathways. The proposed mechanisms involve VEGFR2 signaling, nitric oxide modulation, and growth-hormone-receptor effects on tendon cells.

Human clinical evidence is much thinner. A registered Phase 1 safety trial in healthy adults was launched in 2015 but never published results. A small published intravenous safety pilot exists. There is no completed published human efficacy trial. We discuss this evidence picture honestly with every patient who asks about BPC-157.

We injection near the area of concern when it’s reasonable to do so. The animal work suggests local exposure matters for tendon, ligament, and gut tissue, and clinical practice has followed that pattern.

Cycle length is matched to what’s being addressed. A recent strain might run 4 weeks. A long-standing tendinopathy or persistent gut issue might run 8 weeks, with a break before deciding whether to repeat.

Two things are worth knowing before starting. BPC-157 has no completed published human efficacy trial. And it is on the prohibited substance list for tested athletes (USADA, WADA-monitored). We don’t recommend it for anyone subject to drug testing.

Tissue work often pairs with skin and aesthetic work, especially around recovery from procedures. This protocol is often used to supplement other services like SkinPen microneedling, RF microneedling, and our laser series.